Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

Asthma & Allergy Foundation of America ... Allergy-test-based elimination diets for the treatment of eosinophilic esophagitis: A systematic review of their efficacy. J Clin Med.

A Potential Therapeutic Target for Steroid Resistant Asthma,” published in the December 2024 issue of Allergy and Immunology ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

This can lead to inflammation and an increased risk of eosinophilic asthma. If you have severe asthma or your asthma symptoms do not improve with standard treatments, your healthcare provider may ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Medically reviewed by Qin Rao, MD Eosinophilic esophagitis (EoE) is a chronic (long-term) condition affecting the esophagus, ...

which is similar to the inflammatory processes seen in asthma and eosinophilic rhinosinusitis. This has led to a reevaluation of the diagnostic criteria and treatment approaches for EOM ...

The following is a summary of “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial,” published in ...